Tumors of the brain are highly resistant to therapy. Primary glioblastomas are one of the most deadly tumors with a median survival of just over a year. When systemic cancer spreads to the brain the survival is particularly bleak because even though the systemic metastases can respond to therapy, the ones in the brain rarely do. One of the mechanisms for resistance of these tumors appears to be related to their vasculature and perivascular stromal cells since the cells that survive therapy are often perivascular and the perivascular niche is a location for stem-like resistant cells of the tumor. In this application we will investigate the role of vasculature and the stromal cells of the perivascular niche in primary and metastatic brain tumors. We will use a combination of engineered mouse models, human surgical samples, and human cell line to investigate the contribution of these cells to tumorigenesis and resistance to therapy. In project 1 we will investigate the expression patterns of these cell types in vivo in response to therapy and identify genes that predict response and survival in glioblastoma patients. In project 2 we will investigate the role of the vasculature on the ability for metastatic tumors to form in the brain and for these tumors to respond to therapy. In project 3 we will use genetic tools to modify the genetics of endothelial cells in a way to determine the contributions of angiocrine signaling in both primary and metastatic tumors to the brain.

Public Health Relevance

Glioblastoma is one of the most deadly cancers, and metastatic tumors to the brain are equally devastating and much more common. Both tumor types are highly resistant to therapy. Evidence suggests that one of the reasons for resistance of tumors in the brain resides in the blood vessels and cells surrounding them. We hope to understand the role of perivascular cells in therapeutic resistance to reverse this effect.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (O1))
Program Officer
Mohla, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797
Park, Young Bong; Hohl, Marcel; Padjasek, Micha? et al. (2017) Eukaryotic Rad50 functions as a rod-shaped dimer. Nat Struct Mol Biol 24:248-257
Lis, Raphael; Karrasch, Charles C; Poulos, Michael G et al. (2017) Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature 545:439-445
Shido, Koji; Chavez, Deebly; Cao, Zhongwei et al. (2017) Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration. Signal Transduct Target Ther 2:
Boire, Adrienne; Zou, Yilong; Shieh, Jason et al. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell 168:1101-1113.e13
Kim, Jun Hyun; Grosbart, Malgorzata; Anand, Roopesh et al. (2017) The Mre11-Nbs1 Interface Is Essential for Viability and Tumor Suppression. Cell Rep 18:496-507
Amankulor, Nduka M; Kim, Youngmi; Arora, Sonali et al. (2017) Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 31:774-786
Itkin, Tomer; Gómez-Salinero, Jesús María; Rafii, Shahin (2017) Open the gates: vascular neurocrine signaling mobilizes hematopoietic stem and progenitor cells. J Clin Invest 127:4231-4234
Guo, Peipei; Poulos, Michael G; Palikuqi, Brisa et al. (2017) Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Invest 127:4242-4256
Badri, H; Pitter, K; Holland, E C et al. (2016) Optimization of radiation dosing schedules for proneural glioblastoma. J Math Biol 72:1301-36

Showing the most recent 10 out of 41 publications